Skip to main content
Log in

Enhanced cytotoxicity with methotrexate in conjunction with hypoxanthine in L1210 cells in culture

  • Original Articles
  • Methotrexate-hypoxanthine Combination, L1210 Cells, Cytotoxicity
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

By inhibiting dihydrofolate reductase, methotrexate (MTX) depletes cellular stores of reduced folates, resulting in the inhibition of DNA and RNA synthesis. Inhibition of RNA synthesis arrests cells in the G1 phase of the cell cycle, preventing these cells from entering S phase and rendering them insensitive to MTX. Because MTX cytotoxicity can be enhanced by concurrent administration of hypoxanthine (HX), we examined the hypothesis that this modulation can allow normal rates of RNA synthesis and cell cycle progression from G1 to S phase. For L1210 cells exposed to MTX for 12 h or 24 h, the addition of HX enhanced the cytotoxicity of MTX; however, no enhancement was observed with a 6-h exposure. Inhibition of RNA synthesis by MTX was prevented by concurrent administration of HX. The effect of HX on cell cycle progression was first examined using flow cytometry, which indicated that MTX treatment alone or with concurrent HX caused a buildup of cells with aG1 content of DNA. Because this technique may fail to distinguish between cells in late G1 phase, the G1/S border, or early S, the method of premature chromosome condensation was used to determine cell cycle position based on chromatin morphology. A shift to a higher degree of chromatin decondensation was observed when HX was coadministered with MTX during a 12-h exposure, suggesting progression from G1 towards S. This correlated with the enhancement of MTX cytotoxicity by HX after 12 h exposure. The results of these studies suggest that HX potentiates MTX cytotoxicity by maintaining RNA synthesis, allowing cells that mightordinarily be arrested in G1 to progress into the cytotoxic S phase.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Alabaster O, Tannenbaum E, Habbersett MC, Magrath I, Herman C (1978) Drug-induced changes in DNA fluorescence intensity detected by flow microfluorometry and their implications for analysis of DNA content distributions. Cancer Res 38: 1031

    Google Scholar 

  2. Borsa J, Whitmore GF (1969) Cell killing studies on the mode of action of methotrexate on L-cells in vitro. Cancer Res 29: 737

    Google Scholar 

  3. Chabner BA (1982) Methotrexate. In: Chabner BA (ed) Pharmacologic principles of cancer treatment. Saunders, Philadelphia, p 229

    Google Scholar 

  4. Chu MY, Fischer GA (1968) The incorporation of 3H-cytosine arabinoside and its effect on murine leukemic cells (L5178Y). Biochem Pharmacol 17: 753

    Google Scholar 

  5. Crissman HA, Tobey TA (1974) Cell cycle analysis in 20 minutes. Science 184: 1297

    Google Scholar 

  6. Darznkiewicz Z, Sharpless T, Staiano-Coico L, Melamed MR (1980) Sub-compartments of the G1 phase of cell cycle detected by flow cytometry. Proc Natl Acad Sci USA 77: 6696

    Google Scholar 

  7. Fairchild CR, Maybaum J, Kennedy KA (1986) Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment. Biochem Pharmacol 35:3533

    Google Scholar 

  8. Fry DW, Anderson LA, Borst M, Goldman ID (1983) Analysis of the role of membrane transport and polyglutamation of methotrexate in gut and the Ehrlich tumor in vivo as factors in drug sensitivity and selectivity. Cancer Res 43: 1087

    Google Scholar 

  9. Hittelman WN, Rao PN (1978) Mapping G1 phase by structureal morphology of the prematurely condensed chromosomes. J Cell Physiol 95: 333

    Google Scholar 

  10. Hryniuk WM (1975) The mechanism of action of methotrexate in cultured L5178Y leukemia cells. Cancer Res 35: 1085

    Google Scholar 

  11. Lever JE, Nuki G, Seegmiller JE (1974) Expression of purine over production in series of 8-azaguanine-resistant diploid human lymphoblast lines. Proc Natl Acad Sci USA 71: 2679

    Google Scholar 

  12. Mandel HG, Connors TA, Melzack DH, Merai K (1974) Studies on the mechanism of action of 5-aziridinyl-2,4-dinitrobenzamide in tumor cells. Cancer Res 34: 275

    Google Scholar 

  13. Mead JAR, Venditti JM, Schrecker AW, Goldin A, Keresztesy JC (1963) The effect of reduced derivatives of folic acid on toxicity and antileukemic effect of methotrexate in mice. Biochem Pharmacol 12: 371

    Google Scholar 

  14. Rao PN, Johnson RT (1970) Mammalian cell fusion: studies on the regulation of DNA synthesis and mitosis. Nature 225: 159

    Google Scholar 

  15. Taylor IW, Slowiaczek P, Francis P, Tattersall MHN (1982a) Purine modulation of methotrexate cytotoxicity in mammalian cell lines. Cancer Res 42: 159

    Google Scholar 

  16. Taylor IW, Slowiaczek P, Francis PR, Tattersall MHN (1982b) Biochemical and cell cycle perturbations in methotrexate-treated cells. Mol Pharmacol 21: 204

    Google Scholar 

  17. Taylor IW, Tattersall MHN (1981) Methotrexate cytotoxicity in cultured human leukemic cells studied by flow cytometry. Cancer Res 41: 1549

    Google Scholar 

  18. Werkheiser WC (1963) The biochemical, cellular and pharmacological action and effects of the folic acid antagonists. Cancer Res 23: 1277

    Google Scholar 

  19. Whitehead VM (1977) Synthesis of methotrexate polyglutamates in L1210 murine leukemia cells. Cancer Res 37: 408

    Google Scholar 

  20. Wilkoff LJ, Wilcox WS, Burdeshaw JA, Dixon GJ, Dulmadge EA (1967) Effect of antimetabolites on kinetic behavior of proliferating cultured L1210 leukemia cells. J Natl Cancer Inst 39: 965

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

This research was supported by USPHS Training Grant 5T-32-CA09223.

From a dissertation by CRF presented to the department of Pharmacology, the George Washington University School of Arts and Sciences, in partial fulfillment of the requirements for the PhD. Predoctoral support was provided by Grant 5T-32-CA09223; present address: Clinical Pharmacology Branch, Division of Cancer Treatment, National Cancer Institute, Bldg. 10, Rm.6N116, Bethesda, MD 20892.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fairchild, C.R., Maybaum, J. & Straw, J.A. Enhanced cytotoxicity with methotrexate in conjunction with hypoxanthine in L1210 cells in culture. Cancer Chemother. Pharmacol. 22, 26–32 (1988). https://doi.org/10.1007/BF00254176

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00254176

Keywords

Navigation